💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Imatinib Mesylate

CHEMBL1642 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
589.7 g/mol
LogP
—
Phase
4

This is the mesylate salt of imatinib, the first approved tyrosine kinase inhibitor, used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). By blocking the BCR-ABL oncoprotein and other kinases (c-Kit, PDGFR), it stops cancer cell proliferation. The mesylate salt form provides good oral bioavailability.

分子量

589.7000 g/mol

TPSA

149.00 Ų

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Lymphoma Hypertension Breast Cancer Malaria Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

作用機序

Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

                

                

                

                    
                    

                        
Molecular Formula

                        
C30H35N7O4S

                    

                    
                    

                        
HBD / HBA

                        
3 / 10

                    

                    
                    

                        
回転可能結合数

                        
7

                    

                    
                    
                    

                        
重原子数

                        
42

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This is the mesylate salt of imatinib, the first approved tyrosine kinase inhibitor, used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). By blocking the BCR-ABL oncoprotein and other kinases (c-Kit, PDGFR), it stops cancer cell proliferation. The mesylate salt form provides good oral bioavailability.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Imatinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1642.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 123596.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.